A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009401/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the safety and tolerability of the study drug
(DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to
receive DX-2930 or placebo.
提供机构：
Vivli
创建时间：
2023-11-01
